ABOT 1HCY26 profit rises 17%

According to Mettis Global, Abbott Laboratories (Pakistan) Limited, listed on the PSX as ABOT, lifted its net profit by 17% in the half-year ended June 30, 2026. Net profit reached Rs4.14 billion against Rs3.54 billion a year earlier, while earnings per share climbed to Rs42.29 from Rs36.19. The report links the gain mainly to steady local revenue growth and wider gross margins.

Net sales rose 4% to Rs38.03 billion, with local sales up 6% to Rs37.15 billion while export sales fell 41% to Rs875.69 million. Cost of sales eased 1% to Rs23.58 billion, which lifted gross profit 15% to Rs14.45 billion. Selling and distribution costs climbed 11% to Rs6.15 billion, but a 43% jump in other income still pushed operating profit prior to finance costs up 20% to Rs7.24 billion.

Finance costs fell 5% to Rs35.64 million, while a minimum tax differential levy of Rs159.45 million was absorbed before profit before tax rose 17% to Rs7.04 billion. Income tax expense increased 18% to Rs2.90 billion over the six-month period. Exports fell sharply during the period, while local sales and gross margins supported the overall result.